Dietary conjugated linoleic acid protects against end stage disease of systemic lupus erythematosus in the NZB/W F1 mouse.
Conjugated linoleic acid (CLA) is a naturally occurring fatty acid with anti-carcinogenic, anti-atherosclerotic and immune-enhancing activities. Dietary CLA accelerated the onset of proteinuria in autoimmune-prone NZB/W F1 mice but did not affect anti-DNA antibody production. Body weight of the CLA group was decreased compared to the control group at the time proteinuria first developed. CLA group also had slightly earlier mortality than control fed mice, however the mean days of survival did not differ between CLA and control fed mice. Body weight loss between proteinuria onset and death was approximately twice as much in the control group as in the CLA group. Moreover, duration between proteinuria and death was longer in the CLA than in the control group. Our data suggested that dietary CLA may accelerate the autoimmune symptoms of NZB/W F1 mice, however, CLA protected against the disease related body weight loss and prolonged survival after proteinuria.
Yang
M
M
Department of Animal Science, University of Wisconsin-Madison, 53706-1284, USA.
Pariza
M W
MW
Cook
M E
ME
D000818:Animals; D000974:Antibodies, Antinuclear / Q000096:biosynthesis; D004042:Dietary Fats, Unsaturated / Q000494:pharmacology*; D005260:Female; D019787:Linoleic Acid / Q000494:pharmacology*; D008180:Lupus Erythematosus, Systemic / Q000178:diet therapy* / Q000209:etiology / Q000473:pathology; D051379:Mice; D008814:Mice, Inbred NZB; D011507:Proteinuria / Q000209:etiology; D015431:Weight Loss / Q000187:drug effects
D000974:Antibodies, Antinuclear; D004042:Dietary Fats, Unsaturated; D019787:Linoleic Acid